August 3, 2021 09:43 AM EDTUpdated 05:40 PM

Opinion: Pricing info with new drug approvals: Time for transparency

Zachary Brennan

Senior Editor

For years Congress has raised concerns with the way some drugmakers pay to delay generic versions of their branded blockbusters, as well as other patent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Opinion: Pricing info with new drug approvals: Time for transparency

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Opin­ion: Pric­ing in­fo with new drug ap­provals: Time for trans­paren­cy

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Opinion: Pricing info with new drug approvals: Time for transparency